Novocure Announces Data Presentations at the ESMO 2017 Congress

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that four data presentations on Tumor Treating Fields (TTFields) will be presented at the European Society for Medical Oncology (ESMO) 2017 Congress, September 8 through September 12 in Madrid, Spain. Among the highlights is a poster discussion of the overall survival and quality of life data …

German Federal Joint Committee Announces Decision to Support a Clinical Trial to Study Optune® for the Treatment of Newly Diagnosed Glioblastoma

Proposed trial design will examine the benefit of combining Optune with radiation therapy and temozolomide prior to the initiation of maintenance temozolomide ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced that the German Federal Joint Committee, (Gemeinsamer Bundesausschuss or G-BA), has published its decision to support a clinical trial studying Optune for the treatment …

Novocure to Present at Two Upcoming Investor Conferences in September

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that it will participate in two upcoming investor conferences in September. William Doyle, Novocure’s Executive Chairman, will participate in the Wells Fargo 2017 Healthcare Conference on September 6, 2017, in Boston. Mr. Doyle’s presentation will begin at 10:15 a.m. EDT and will be followed by a Q&A …

Novocure™ Announces National Reimbursement for Optune® in Austria

The decision marks Novocure’s first national coverage policy ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today it has signed a contract with the Federation of the Austrian Social Insurance Institutions which grants reimbursement across Austria for Optune – Novocure’s Tumor Treating Fields (TTFields) delivery system – for the treatment of adults with newly diagnosed …

Novocure to Present at the 2017 Wedbush PacGrow Healthcare Conference

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that it will participate in the 2017 Wedbush PacGrow Healthcare Conference on August 15, 2017, in New York City. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts. Mr. Doyle’s presentation will begin at 12:45 p.m. EDT and will …

Novocure Reports Second Quarter 2017 Financial Results and Provides Company Update

1,460 active patients at June 30, 2017, an increase of 64 percent from June 30, 2016, and 15 percent from March 31, 2017 Second quarter 2017 net revenues of $38.4 million, reflecting 114 percent growth versus second quarter 2016 and 10 percent growth versus first quarter 2017 ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today …

Novocure™ Announces a Phase 1b Clinical Trial to Evaluate the Safety of Marizomib and Temozolomide in Combination with Optune® as Adjuvant Therapy in Patients with Glioblastoma

This trial is the first to study Optune in combination with an investigational drug ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today a new arm for a phase 1b study to evaluate the safety of marizomib and temozolomide in combination with Optune, Novocure’s Tumor Treating Fields (TTFields) delivery system, as adjuvant treatment for patients with …

Novocure’s Optune® Now Available at More Than 600 Cancer Treatment Centers in the U.S.

Company broadens geographic reach of Optune in community setting, making therapy more accessible to patients Internationally, GBM patients can access Optune at an additional 350 medical institutions ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure™ (NASDAQ: NVCR) announced today that physicians at more than 600 cancer treatment centers in the U.S. have been certified to prescribe Optune to …

Data on Delivery of Tumor Treating Fields to be Presented at the 39th Annual International Conference of the IEEE Engineering in Medicine and Biology Society

Three oral presentations underscore Novocure’s commitment to further understanding the physical application of Tumor Treating Fields to enhance efficacy ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that three oral presentations on Tumor Treating Fields (TTFields) will be given at the 39th Annual International Conference of the IEEE Engineering in Medicine and Biology Society …

Novocure to Report Second Quarter 2017 Financial Results

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2017 on Thursday, July 27, 2017, before the U.S.-based financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three and six months ended June 30, 2017, …